CY1117826T1 - Ενωσεις μορφiνανης - Google Patents

Ενωσεις μορφiνανης

Info

Publication number
CY1117826T1
CY1117826T1 CY20161100624T CY161100624T CY1117826T1 CY 1117826 T1 CY1117826 T1 CY 1117826T1 CY 20161100624 T CY20161100624 T CY 20161100624T CY 161100624 T CY161100624 T CY 161100624T CY 1117826 T1 CY1117826 T1 CY 1117826T1
Authority
CY
Cyprus
Prior art keywords
present disclosure
diseases
morfinanis
units
compositions
Prior art date
Application number
CY20161100624T
Other languages
English (en)
Inventor
Roger Tung
Original Assignee
Concert Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08747238A external-priority patent/EP2152709B1/en
Application filed by Concert Pharmaceuticals Inc. filed Critical Concert Pharmaceuticals Inc.
Publication of CY1117826T1 publication Critical patent/CY1117826T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/491—Blood by separating the blood components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine

Abstract

Η παρούσα αποκάλυψη αφορά καινούριες ενώσεις της μορφινάνης και παράγωγά τους, καθώς και φαρμακευτικά αποδεκτά άλατα, επιδιαλυτώματα και υδρίτες αυτών. Η παρούσα αποκάλυψη προβλέπει επίσης συνθέσεις αποτελούμενες από κάποια ένωση της παρούσας αποκάλυψης και τη χρήση τέτοιων συνθέσεων σε μεθόδους για την αντιμετώπιση νοσημάτων και παθήσεων οι οποίες είχαν επωφελώς αντιμετωπιστεί με τη χορήγηση κάποιου αγωνιστή υποδοχέα σ1, ο οποίος έχει επίσης και ενεργότητα ανταγωνιστή NMDA.
CY20161100624T 2007-05-01 2016-07-05 Ενωσεις μορφiνανης CY1117826T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91513007P 2007-05-01 2007-05-01
US91666207P 2007-05-08 2007-05-08
US97604407P 2007-09-28 2007-09-28
EP11000764.8A EP2357183B1 (en) 2007-05-01 2008-04-30 Morphinan compounds
EP08747238A EP2152709B1 (en) 2007-05-01 2008-04-30 Morphinan compounds

Publications (1)

Publication Number Publication Date
CY1117826T1 true CY1117826T1 (el) 2017-05-17

Family

ID=51894365

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100624T CY1117826T1 (el) 2007-05-01 2016-07-05 Ενωσεις μορφiνανης

Country Status (15)

Country Link
US (6) US9314440B2 (el)
EP (5) EP3093290B1 (el)
BR (1) BRPI0811478B8 (el)
CA (3) CA2945581C (el)
CY (1) CY1117826T1 (el)
DK (4) DK2522668T3 (el)
ES (5) ES2577477T3 (el)
FI (1) FI3825306T3 (el)
HK (5) HK1178154A1 (el)
HR (5) HRP20230745T3 (el)
HU (3) HUE063526T2 (el)
LT (1) LT3825306T (el)
PL (3) PL2792662T3 (el)
PT (5) PT2792662T (el)
SI (2) SI3825306T1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE063526T2 (hu) 2007-05-01 2024-01-28 Concert Pharmaceuticals Ind Inc Morfinvegyületek
MX341177B (es) * 2007-05-01 2016-08-10 Concert Pharmaceuticals Inc Compuestos de morfina.
WO2017020002A1 (en) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
CA2994153A1 (en) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
WO2017064876A1 (ja) 2015-10-14 2017-04-20 学校法人 久留米大学 グレリンを有効成分として含有するレット症候群（ｒｔｔ）の予防・治療剤
EP3570842A1 (en) 2017-01-19 2019-11-27 Donald Danforth Plant Science Center Morphinan n-demethylase isolated from themethylobacterium

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US38115A (en) 1863-04-07 Improvement in turning edges of plates or metal sheets
GB713146A (en) 1951-10-18 1954-08-04 Roche Products Ltd Anti-cough agents comprising (ú½)-3-hydroxy-n-methyl-morphinane ethers and process for the manufacture thereof
US4316888A (en) 1980-04-15 1982-02-23 Nelson Research & Development Co. Method and composition of reducing pain
US4446140A (en) 1981-12-10 1984-05-01 Nelson Research & Development Company Method and composition for treating mouth pain
JPS6089474A (ja) 1983-10-20 1985-05-20 Toyo Pharma- Kk モルフイナン誘導体，その製造方法，及び該化合物を含有する抗腫瘍剤
US4694010A (en) 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
US4898860A (en) 1985-08-16 1990-02-06 New York University Anticonvulsant composition and method
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5366980A (en) 1991-06-17 1994-11-22 Smith Richard A Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5166207A (en) 1991-06-17 1992-11-24 Neurotherapeutics, Inc. Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
US5350756A (en) 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US5336980A (en) 1992-12-10 1994-08-09 Leopold Kostal Gmbh & Co. Apparatus and method for controlling a windshield wiping system
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
USRE38115E1 (en) 1994-09-22 2003-05-06 Center For Neurologic Study Dextromethorphan and an oxidase inhibitor for treating intractable conditions
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
CH690817A5 (de) 1996-09-03 2001-01-31 Flachsmann Ag Emil Verfahren zur Herstellung eines stabilen, homogenen, von Folgeprodukten freien oder nahezu freien Extraktes.
US6187782B1 (en) 1997-03-27 2001-02-13 Toray Industries, Inc. Morphinane derivatives and medicinal use thereof
US6884429B2 (en) 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
EP1051163A2 (en) 1998-01-29 2000-11-15 Sepracor, Inc. Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
DE60001623T2 (de) 1999-12-03 2003-12-18 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
US6362226B2 (en) 1999-12-08 2002-03-26 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US20050129783A1 (en) 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US6780871B2 (en) 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
US20040087479A1 (en) 2001-04-30 2004-05-06 Sosnowski Robert E. Composition and method for reducing the risk or progression of cardiovascular, glaucoma, tardive dyskinesia and other diseases
US6583152B2 (en) 2001-04-30 2003-06-24 Dexgen Pharmaceuticals, Inc. Composition for reducing the risk or progression of cardiovascular diseases
JP4101661B2 (ja) 2001-05-03 2008-06-18 エフ．ホフマン−ラ ロシュ アーゲー 非晶質メシル酸ネルフィナビルの製薬剤形
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
UA77234C2 (en) 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
MXPA04011327A (es) 2002-05-17 2005-08-15 Jenken Biosciences Inc Opioides y compuestos similares a opioides y usos de los mismos.
TWI326214B (en) 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
DE102004009445A1 (de) 2004-02-27 2005-09-29 Chemetall Gmbh Verfahren zur Herstellung von Alkyllithiumverbindungen und Aryllithiumverbindungen durch Reaktionsverfolgung mittels IR-Spektroskopie
CA2576232C (en) 2004-05-14 2009-10-27 Green Cross Corp. Neuroprotective properties of dextrorotatory morphinans
JP2008514706A (ja) 2004-09-29 2008-05-08 コーディス・コーポレイション 安定非晶質ラパマイシン様化合物の薬学的投与形態
US20070191411A1 (en) 2004-10-07 2007-08-16 Smith Richard A Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor
US7114547B2 (en) 2005-01-11 2006-10-03 Sullivan Michael R Casting ring
AU2006274037B2 (en) 2005-07-26 2012-04-26 Takeda Gmbh Isotopically substituted pantoprazole
JP5301991B2 (ja) 2005-07-29 2013-09-25 コンサート ファーマシューティカルズ インコーポレイテッド 新規なベンゾ［ｄ］［１，３］−ジオキソール誘導体
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
AU2007285845A1 (en) 2006-08-16 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of opioid analgesics
WO2008030382A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008097924A2 (en) 2007-02-05 2008-08-14 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
HUE063526T2 (hu) 2007-05-01 2024-01-28 Concert Pharmaceuticals Ind Inc Morfinvegyületek
CN102964302B (zh) 2007-05-01 2015-10-21 康塞特医药品公司 吗啡烷化合物
PL3248978T3 (pl) 2008-09-19 2019-12-31 Concert Pharmaceuticals Inc. Zdeuterowane związki morfinanu
US20120083487A1 (en) 2008-10-30 2012-04-05 Amanda Thomas Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury
JP6525419B2 (ja) 2015-01-15 2019-06-05 株式会社半導体エネルギー研究所 二次電池

Also Published As

Publication number Publication date
DK2792662T3 (da) 2016-07-25
SI3825306T1 (sl) 2023-10-30
BRPI0811478A2 (pt) 2014-11-04
CA3208128A1 (en) 2008-11-13
ES2951028T3 (es) 2023-10-17
ES2545617T3 (es) 2015-09-14
BRPI0811478B8 (pt) 2021-05-25
PL3825306T3 (pl) 2023-09-11
CA3056205C (en) 2023-09-26
EP3093290A1 (en) 2016-11-16
CA2945581A1 (en) 2008-11-13
HK1155442A1 (en) 2012-05-18
SI2792662T1 (sl) 2016-10-28
ES2523286T3 (es) 2014-11-24
EP2792662A1 (en) 2014-10-22
PL2357183T3 (pl) 2015-12-31
HK1201058A1 (zh) 2015-08-21
ES2536984T3 (es) 2015-06-01
US20140329846A1 (en) 2014-11-06
US20240093265A1 (en) 2024-03-21
US20240117407A1 (en) 2024-04-11
US9868976B2 (en) 2018-01-16
FI3825306T3 (fi) 2023-08-23
HRP20160521T1 (hr) 2016-08-12
US20210348208A1 (en) 2021-11-11
HUE063526T2 (hu) 2024-01-28
PT3825306T (pt) 2023-07-24
CA3056205A1 (en) 2008-11-13
HRP20140903T1 (hr) 2014-11-21
ES2577477T3 (es) 2016-07-15
EP3093290B1 (en) 2018-01-24
HRP20150848T1 (hr) 2015-09-25
HRP20230745T3 (hr) 2023-10-27
DK2357183T3 (en) 2015-09-07
DK3825306T3 (da) 2023-09-11
DK2522668T3 (en) 2015-05-26
EP3825306B8 (en) 2023-08-02
HK1178889A1 (en) 2013-09-19
BRPI0811478A8 (pt) 2019-10-15
LT3825306T (lt) 2023-08-10
EP3357923B1 (en) 2019-11-13
PT2522668E (pt) 2015-06-09
HRP20150809T1 (hr) 2016-02-12
PT2792662T (pt) 2016-07-07
HUE029782T2 (en) 2017-04-28
US20180327809A1 (en) 2018-11-15
HK1259133A1 (zh) 2019-11-29
HUE025569T2 (en) 2016-02-29
EP2357183A1 (en) 2011-08-17
BRPI0811478B1 (pt) 2020-12-29
HRP20160521T8 (hr) 2016-10-07
HK1178154A1 (en) 2013-09-06
US20170037449A1 (en) 2017-02-09
EP3357923A1 (en) 2018-08-08
PT2357183E (pt) 2015-09-28
EP3825306A1 (en) 2021-05-26
PT2522667E (pt) 2014-11-11
EP2357183B1 (en) 2015-07-01
PL2792662T3 (pl) 2016-10-31
EP3825306B1 (en) 2023-06-07
EP2792662B1 (en) 2016-04-06
CA2945581C (en) 2021-11-16
US9314440B2 (en) 2016-04-19
US11473123B2 (en) 2022-10-18

Similar Documents

Publication Publication Date Title
CY1117826T1 (el) Ενωσεις μορφiνανης
ATE546449T1 (de) Morphinanverbindungen
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
EA201690033A3 (ru) Морфинановые соединения
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1115262T1 (el) Ανταγωνιστες trpv1 και χρησεις αυτων
DK1856090T3 (da) Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
EP2328414A4 (en) SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
MX2010006230A (es) Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
CY1118314T1 (el) Συνδυασμοι αγωνιστων υποδοχεα σεροτονινης για την αγωγη κινητικων διαταραχων
CY1113504T1 (el) Παραγωγο προπανο-1,3-διονης ή αλας αυτου
ATE399156T1 (de) Neue indol- oder benzimidazol-derivate
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
CY1124301T1 (el) Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
NO20055207L (no) Oralt farmasoytisk preparat for protonpumpeantagonister
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu
BRPI0906632A2 (pt) Imidazolinil metil aril sulfonamidas
CY1115153T1 (el) Μεθοδοι για την αγωγη δερματολογικων διαταραχων
EA201000720A1 (ru) 4,4-дизамещённые пиперидины как ингибиторы ренина